{"id":"generic-haart-triomune-d4t-3tc-nvp","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Lactic acidosis"},{"rate":null,"effect":"Pancreatitis"}]},"_chembl":{"chemblId":"CHEMBL4567342","moleculeType":"Unknown","molecularWeight":"431.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The combination contains stavudine (d4T), a nucleoside reverse transcriptase inhibitor; lamivudine (3TC), a nucleoside reverse transcriptase inhibitor; and nevirapine (NVP), a non-nucleoside reverse transcriptase inhibitor. Together, these agents block HIV reverse transcriptase through different mechanisms, preventing the virus from converting its RNA genome into DNA and integrating into host cells, thereby suppressing viral replication and allowing immune reconstitution.","oneSentence":"Triomune is a fixed-dose combination antiretroviral therapy that inhibits HIV reverse transcriptase and protease to suppress viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:08.178Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT00380770","phase":"PHASE4","title":"HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT","status":"COMPLETED","sponsor":"University of KwaZulu","startDate":"2003-01","conditions":"HIV, AIDS, Kaposi's Sarcoma","enrollment":112}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Generic HAART Triomune : d4T, 3TC, NVP","genericName":"Generic HAART Triomune : d4T, 3TC, NVP","companyName":"University of KwaZulu","companyId":"university-of-kwazulu","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triomune is a fixed-dose combination antiretroviral therapy that inhibits HIV reverse transcriptase and protease to suppress viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}